$1.43
-0.03 (-2.05%)
Open$1.44
Previous Close$1.46
Day High$1.48
Day Low$1.39
52W High$2.72
52W Low$0.56
Volume—
Avg Volume48.84M
Market Cap273.47M
P/E Ratio—
EPS$-1.17
SectorBiotechnology
Analyst Ratings
Buy
7 analysts
Price Target
+1,271.3% upside
Current
$1.43
$1.43
Target
$19.61
$19.61
$14.26
$19.61 avg
$29.32
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 315.1K | 1.70M | 29.02M |
| Net Income | -407,771,247 | -1,980,540,325 | -227,719 |
| Profit Margin | -130,006.0% | -123,505.7% | -0.8% |
| EBITDA | -409,976,998 | -2,101,878,834 | -290,155 |
| Free Cash Flow | — | — | -255,634 |
| Rev Growth | -81.5% | -81.5% | +16.9% |
| Debt/Equity | — | — | 0.72 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.55 | -0.16% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $456.60 | -1.24% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $169.42 | +1.10% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $531.97 | -1.08% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $951.08 | -0.14% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $159.73 | -3.22% | 7.7 | 20.98B |